myelodysplastic/myeloproliferative neoplasm (Cancer)
Information
- Disease name
- myelodysplastic/myeloproliferative neoplasm
- Disease ID
- DOID:4972
- Description
- "A myeloid neoplasm that results_in the overproduction of white blood cells." [url:http\://www.bloodjournal.org/content/114/5/937.long, url:http\://www.bloodjournal.org/content/127/20/2391, url:http\://www.bloodjournal.org/content/128/3/462, url:https\://www.cancer.gov/types/myeloproliferative/patient/mds-mpd-treatment-pdq]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03560752 | Active, not recruiting | Phase 1 | CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant | August 20, 2018 | June 18, 2024 |
| NCT02158858 | Active, not recruiting | Phase 1/Phase 2 | A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis | July 16, 2014 | October 31, 2024 |
| NCT03289910 | Active, not recruiting | Phase 2 | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | September 24, 2018 | December 21, 2024 |
| NCT02861417 | Active, not recruiting | Phase 2 | Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | August 5, 2016 | August 31, 2025 |
| NCT02129101 | Completed | Phase 1 | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies | May 2014 | October 25, 2019 |
| NCT02257138 | Completed | Phase 1/Phase 2 | Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia | February 12, 2015 | March 19, 2021 |
| NCT02666950 | Completed | Phase 2 | WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome | May 5, 2017 | October 17, 2018 |
| NCT00075478 | Completed | Phase 3 | Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer | October 2003 | February 2, 2014 |
| NCT00096161 | Completed | Phase 2 | Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant | May 2003 | August 2015 |
| NCT01527045 | Completed | Phase 2 | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies | September 25, 2012 | April 2019 |
| NCT01712308 | Completed | Phase 2 | Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia | February 21, 2013 | May 24, 2022 |
| NCT04022785 | Completed | Phase 1 | PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | September 9, 2019 | October 24, 2022 |
| NCT04926194 | Completed | Phase 2 | Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm | March 11, 2021 | June 9, 2021 |
| NCT05875805 | Not yet recruiting | N/A | A Telehealth Advance Care Planning Intervention | April 1, 2024 | December 31, 2025 |
| NCT05038592 | Recruiting | Phase 1/Phase 2 | Tagraxofusp and Decitabine for the Treatment of Chronic Myelomonocytic Leukemia | March 4, 2022 | January 29, 2025 |
| NCT03630991 | Recruiting | Phase 1 | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy | October 11, 2018 | April 30, 2025 |
| NCT03246906 | Recruiting | Phase 2 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | September 11, 2017 | October 11, 2026 |
| NCT03964506 | Recruiting | Early Phase 1 | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant | July 1, 2020 | March 1, 2025 |
| NCT04282187 | Recruiting | Phase 2 | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | March 24, 2020 | November 11, 2026 |
| NCT02727803 | Recruiting | Phase 2 | Personalized NK Cell Therapy in CBT | May 19, 2016 | May 31, 2025 |
| NCT04771130 | Recruiting | Phase 1/Phase 2 | A Study of BGB-11417 in Participants With Myeloid Malignancies | May 24, 2021 | August 2025 |
| NCT04771572 | Recruiting | Phase 1 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | August 23, 2021 | October 1, 2025 |
| NCT06034470 | Recruiting | Phase 1 | Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms | December 18, 2023 | December 31, 2027 |
| NCT04902833 | Recruiting | Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms | February 1, 2022 | December 31, 2025 | |
| NCT04637009 | Terminated | Phase 1 | A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms | December 21, 2020 | February 20, 2023 |
| NCT03519984 | Terminated | Phase 1 | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia | May 9, 2018 | November 24, 2020 |
| NCT01894477 | Unknown status | Phase 2 | Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia | November 2013 | June 2022 |
| NCT03807063 | Withdrawn | Phase 1 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | January 2, 2020 | December 31, 2021 |
- Disase is a (Disease Ontology)
- DOID:0070004
- Cross Reference ID (Disease Ontology)
- MESH:D054437
- Cross Reference ID (Disease Ontology)
- NCI:C27262
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:445738007
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C1301355
- Exact Synonym (Disease Ontology)
- myelodysplastic myeloproliferative cancer
- Exact Synonym (Disease Ontology)
- Myeloproliferative/Myelodysplastic syndromes
- Disase Synonym (Disease Ontology)
- myelodysplastic myeloproliferative disease